Column Group III Gp, LP
CIK: 0001790965
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (45 total)
- Oct 20, 2026SRZN
Surrozen, Inc./DE
In-the-Money(X)Indirect517.2K shares at avg. $11.60$6.0M - Oct 20, 2026SRZN
Surrozen, Inc./DE
In-the-Money(X)Indirect548.7K shares at avg. $11.60$6.4M - Oct 20, 2026SRZN
Surrozen, Inc./DE
In-the-Money(X)Indirect485.8K shares at avg. $11.60$5.6M - Feb 25, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect1.9M shares at avg. $0.56$1.0M - Feb 25, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect1.6M shares at avg. $0.56$928K - Feb 24, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect349.2K shares at avg. $0.62$215K - Feb 24, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect309.2K shares at avg. $0.62$190K - Feb 23, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect162.3K shares at avg. $0.60$97K - Feb 23, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect143.7K shares at avg. $0.60$86K - Feb 20, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect277.8K shares at avg. $0.61$171K - Feb 20, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect246K shares at avg. $0.61$151K - Feb 11, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect1.9M shares at avg. $0.68$1.3M - Feb 11, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect2.2M shares at avg. $0.68$1.5M - Feb 10, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect182.3K shares at avg. $0.82$149K - Feb 10, 2026TNYA
Tenaya Therapeutics, Inc.
Sale(S)Indirect161.4K shares at avg. $0.82$132K - Jan 20, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect8.5K shares at avg. $19.60$166K - Jan 20, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect9.6K shares at avg. $19.60$188K - Jan 16, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect1.2K shares at avg. $20.00$24K - Jan 16, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect1.4K shares at avg. $20.00$27K - Jan 15, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect5.6K shares at avg. $19.89$111K - Jan 15, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect6.3K shares at avg. $19.89$125K - Jan 14, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect2.6K shares at avg. $19.99$52K - Jan 14, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect2.9K shares at avg. $19.99$59K - Jan 13, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect6.6K shares at avg. $19.80$131K - Jan 13, 2026SRZN
Surrozen, Inc./DE
Purchase(P)Indirect5.9K shares at avg. $19.80$116K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 20, 2026 |  SRZN Surrozen, Inc./DE | In-the-Money(X) | 517,241 | $11.60 | $5,999,996 | Indirect |
| Oct 20, 2026 | SRZN Surrozen, Inc./DE | In-the-Money(X) | 548,653 | $11.60 | $6,364,375 | Indirect |
| Oct 20, 2026 | SRZN Surrozen, Inc./DE | In-the-Money(X) | 485,830 | $11.60 | $5,635,628 | Indirect |
| Feb 25, 2026 |  TNYA Tenaya Therapeutics, Inc. | Sale(S) | 1,862,545 | $0.56 | $1,047,495 | Indirect |
| Feb 25, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 1,649,281 | $0.56 | $927,556 | Indirect |
| Feb 24, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 349,212 | $0.62 | $214,870 | Indirect |
| Feb 24, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 309,228 | $0.62 | $190,268 | Indirect |
| Feb 23, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 162,291 | $0.60 | $96,920 | Indirect |
| Feb 23, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 143,709 | $0.60 | $85,823 | Indirect |
| Feb 20, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 277,769 | $0.61 | $170,800 | Indirect |
| Feb 20, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 245,965 | $0.61 | $151,244 | Indirect |
| Feb 11, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 1,905,115 | $0.68 | $1,297,002 | Indirect |
| Feb 11, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 2,151,458 | $0.68 | $1,464,713 | Indirect |
| Feb 10, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 182,295 | $0.82 | $148,771 | Indirect |
| Feb 10, 2026 | TNYA Tenaya Therapeutics, Inc. | Sale(S) | 161,422 | $0.82 | $131,736 | Indirect |
| Jan 20, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 8,484 | $19.60 | $166,286 | Indirect |
| Jan 20, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 9,568 | $19.60 | $187,532 | Indirect |
| Jan 16, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 1,204 | $20.00 | $24,080 | Indirect |
| Jan 16, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 1,358 | $20.00 | $27,160 | Indirect |
| Jan 15, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 5,590 | $19.89 | $111,180 | Indirect |
| Jan 15, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 6,303 | $19.89 | $125,360 | Indirect |
| Jan 14, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 2,596 | $19.99 | $51,890 | Indirect |
| Jan 14, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 2,927 | $19.99 | $58,506 | Indirect |
| Jan 13, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 6,609 | $19.80 | $130,885 | Indirect |
| Jan 13, 2026 | SRZN Surrozen, Inc./DE | Purchase(P) | 5,861 | $19.80 | $116,072 | Indirect |
1-25 of 45 transactions
About COLUMN GROUP III GP, LP
COLUMN GROUP III GP, LP (SEC CIK 0001790965) files insider reports with the SEC as 10% Owner of Surrozen, Inc./DE (SRZN) and 10% Owner of Tenaya Therapeutics, Inc. (TNYA).
Signal8 holds 11 ownership filings by COLUMN GROUP III GP, LP, all Form 4s, filed between Mar 7, 2025 and Oct 22, 2026. Those filings report 45 transactions, from Mar 5, 2025 to Oct 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on COLUMN GROUP III GP, LP's filings is in SAN FRANCISCO, CA.
Recent filings by COLUMN GROUP III GP, LP
- Oct 20, 2026: Option exercises of SRZN shares (3 lines, Form 4, code X).
- Feb 25, 2026: Open-market sales of TNYA shares (2 lines, Form 4, code S).
- Feb 24, 2026: Open-market sales of TNYA shares (2 lines, Form 4, code S).
- Feb 23, 2026: Open-market sales of TNYA shares (2 lines, Form 4, code S).
- Feb 20, 2026: Open-market sales of TNYA shares (2 lines, Form 4, code S).
Other insiders filing for Surrozen, Inc./DE (SRZN)
- Kutzkey Tim, Director
- TCG Crossover GP II, LLC, 10% Owner
- Maleki Andrew Pedrum, Chief Financial Officer
- Li Yang, Exec. Vice President, Research
- Williams Charles O, Chief Operating Officer
- Parker Craig C, Chief Executive Officer